Your browser doesn't support javascript.
loading
Early detection of hepatocellular carcinoma via no end-repair enzymatic methylation sequencing of cell-free DNA and pre-trained neural network.
Deng, Zhenzhong; Ji, Yongkun; Han, Bing; Tan, Zhongming; Ren, Yuqi; Gao, Jinghan; Chen, Nan; Ma, Cong; Zhang, Yichi; Yao, Yunhai; Lu, Hong; Huang, Heqing; Xu, Midie; Chen, Lei; Zheng, Leizhen; Gu, Jianchun; Xiong, Deyi; Zhao, Jianxin; Gu, Jinyang; Chen, Zutao; Wang, Ke.
Afiliação
  • Deng Z; Department of Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Ji Y; BamRock Research Department, Suzhou BamRock Biotechnology Ltd., Suzhou, Jiangsu Province, China.
  • Han B; Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Tan Z; Department of Transplantation, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Ren Y; Hepatobiliary Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
  • Gao J; College of Intelligence and Computing, Tianjin University, Tianjin, China.
  • Chen N; Department of Software Engineering, Tsinghua University, Beijing, China.
  • Ma C; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.
  • Zhang Y; Suzhou Known Biotechnology Ltd, Suzhou, Jiangsu Province, China.
  • Yao Y; Department of Transplantation, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Lu H; Infectious Disease Department, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.
  • Huang H; Infectious Disease Department, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.
  • Xu M; Infectious Disease Department, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.
  • Chen L; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Zheng L; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Gu J; Department of Pathology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Xiong D; Department of Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Zhao J; Department of Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. gujianchun@126.com.
  • Gu J; College of Intelligence and Computing, Tianjin University, Tianjin, China. dyxiong@tju.edu.cn.
  • Chen Z; Department of Interventional Medicine, the affiliated hospital of infectious diseases of Soochow University, Suzhou, 215131, Jiangsu Province, China. zhao13776@163.com.
  • Wang K; Department of Transplantation, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. gjynyd@126.com.
Genome Med ; 15(1): 93, 2023 11 08.
Article em En | MEDLINE | ID: mdl-37936230
ABSTRACT

BACKGROUND:

Early detection of hepatocellular carcinoma (HCC) is important in order to improve patient prognosis and survival rate. Methylation sequencing combined with neural networks to identify cell-free DNA (cfDNA) carrying aberrant methylation offers an appealing and non-invasive approach for HCC detection. However, some limitations exist in traditional methylation detection technologies and models, which may impede their performance in the read-level detection of HCC.

METHODS:

We developed a low DNA damage and high-fidelity methylation detection method called No End-repair Enzymatic Methyl-seq (NEEM-seq). We further developed a read-level neural detection model called DeepTrace that can better identify HCC-derived sequencing reads through a pre-trained and fine-tuned neural network. After pre-training on 11 million reads from NEEM-seq, DeepTrace was fine-tuned using 1.2 million HCC-derived reads from tumor tissue DNA after noise reduction, and 2.7 million non-tumor reads from non-tumor cfDNA. We validated the model using data from 130 individuals with cfDNA whole-genome NEEM-seq at around 1.6X depth.

RESULTS:

NEEM-seq overcomes the drawbacks of traditional enzymatic methylation sequencing methods by avoiding the introduction of unmethylation errors in cfDNA. DeepTrace outperformed other models in identifying HCC-derived reads and detecting HCC individuals. Based on the whole-genome NEEM-seq data of cfDNA, our model showed high accuracy of 96.2%, sensitivity of 93.6%, and specificity of 98.5% in the validation cohort consisting of 62 HCC patients, 48 liver disease patients, and 20 healthy individuals. In the early stage of HCC (BCLC 0/A and TNM I), the sensitivity of DeepTrace was 89.6 and 89.5% respectively, outperforming Alpha Fetoprotein (AFP) which showed much lower sensitivity in both BCLC 0/A (50.5%) and TNM I (44.7%).

CONCLUSIONS:

By combining high-fidelity methylation data from NEEM-seq with the DeepTrace model, our method has great potential for HCC early detection with high sensitivity and specificity, making it potentially suitable for clinical applications. DeepTrace https//github.com/Bamrock/DeepTrace.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Ácidos Nucleicos Livres / Neoplasias Hepáticas Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Ácidos Nucleicos Livres / Neoplasias Hepáticas Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article